Panavance Therapeutics
Our Science
Pipeline
About Misetionamide
MOA
About
About Panavance
Leadership
Board of Directors
Advisors & Collaborators
Contact Panavance
Resources
Publications
Brochures
Videos
Press Releases
Events
Participate
Let’s engage
.
GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells
December 31, 2023
/
0 Minute Read